Mechanism of Action and Pharmacology
Resmetirom is a selective partial agonist of thyroid hormone receptor-beta (THR-β), the predominant thyroid hormone receptor isoform in the liver 1. In vitro, resmetirom achieves 83.8% of maximum T3 response at THR-β (EC50 0.21 µM) versus only 48.6% at THR-α (EC50 3.74 µM), conferring hepatoselectivity 1. By preferentially activating hepatic THR-β, resmetirom reduces intrahepatic triglycerides, suppresses de novo lipogenesis, attenuates inflammation, and decreases atherogenic lipids, while largely sparing cardiac and bone tissue—effects mediated predominantly through THR-α 12.
Pharmacokinetics and Dosing
REZDIFFRA is supplied as 60 mg, 80 mg, and 100 mg tablets. Weight-based dosing applies: 80 mg once daily for patients weighing <100 kg and 100 mg once daily for those ≥100 kg 1. Tablets must be swallowed whole. The drug can be administered with or without food; a high-fat meal reduces Cmax by 33%, AUC by 11%, and delays Tmax by approximately 2 hours, without clinical significance 1. Steady state is achieved in 3–6 days, with a median Tmax of ~4 hours and terminal half-life of 4.5 hours. Resmetirom is >99% protein-bound and is metabolized by CYP2C8; in vitro, it is not metabolized by other CYP enzymes. Its major metabolite, MGL-3623, has 28-fold lower THR-β potency and represents 33–51% of parent AUC at steady state 1.
Key Drug–Drug Interactions (DDIs)
| Perpetrator/Substrate | Effect on Resmetirom or Co-drug | Clinical Action |
|---|---|---|
| Strong CYP2C8 inhibitors (e.g., gemfibrozil) | Substantial resmetirom AUC increase | Not recommended |
| Moderate CYP2C8 inhibitors (e.g., clopidogrel) | AUC +1.7-fold, Cmax +1.3-fold | Reduce dose: <100 kg → 60 mg; ≥100 kg → 80 mg |
| Rosuvastatin (OATP1B1/1B3, BCRP substrate) | Cmax +1.8x, AUC +1.4x | Limit to ≤20 mg/day |
| Simvastatin (OATP1B1/1B3 substrate) | Cmax +1.4x, AUC +1.7x | Limit to ≤20 mg/day |
| Pravastatin (OATP1B1/1B3 substrate) | Cmax +1.3x, AUC +1.4x | Limit to ≤40 mg/day |
| Atorvastatin (BCRP/OATP1B1/1B3 substrate) | AUC +1.4x; lactone Cmax +2.0x | Limit to ≤40 mg/day |
| Pioglitazone (CYP2C8 substrate) | AUC +1.5x | Monitor for adverse reactions |
Monitor patients on concomitant statins or CYP2C8 substrates for myopathy, rhabdomyolysis, and hepatotoxicity 1.
Efficacy Evidence Base
Pivotal Phase 3: MAESTRO-NASH The FDA approval was based on a 54-month, randomized, double-blind, placebo-controlled trial (n=966 biopsy-confirmed NASH; fibrosis stages F1B–F3), with primary histologic endpoints assessed at Week 52 36.
| Endpoint | Placebo | Resmetirom 80 mg | Resmetirom 100 mg |
|---|---|---|---|
| NASH resolution without fibrosis worsening | 9.7% | 25.9% (P<0.001) | 29.9% (P<0.001) |
| ≥1-stage fibrosis improvement without NASH worsening | 14.2% | 24.2% (P<0.001) | 25.9% (P<0.001) |
| MRI-PDFF reduction (mean) | −10% | −42% | −51% |
| LDL-C change (week 24) | +0.1% | −13.6% (P<0.001) | −16.3% (P<0.001) |
Absolute treatment differences were approximately 16–20% for NASH resolution and 10–12% for fibrosis improvement. Efficacy was generally consistent across subgroups including baseline fibrosis stage and diabetes status 12. Histologic responders also experienced clinically meaningful health-related quality-of-life (HRQL) improvements: CLDQ-NAFLD Worry domain (+0.46; 41% MCID), LDQOL total (+2.2; 35% MCID), and LDQOL Health Distress (+8.1; 38% MCID) 8.
In the open-label compensated cirrhosis arm (MAESTRO-NAFLD-1), mean liver stiffness improved by −6.7 kPa at two years (p<0.05), and 51% achieved ≥25% liver-stiffness improvement; 65% of patients with clinically significant portal hypertension (CSPH) shifted to lower-risk categories by year two 2. However, no randomized comparator data are available for the cirrhosis subpopulation.
Contextualizing Against Standard of Care
No head-to-head data against GLP-1 receptor agonists (semaglutide, tirzepatide) or pioglitazone were found in the retrieved materials. Cross-trial comparisons are confounded by different populations, endpoints, and trial designs. Emerging Phase 2 agents (ervogastat + clesacostat combination, efruxifermin) show histologic signal, but remain investigational 1011. Durability of histologic benefit beyond 12–24 months and effects on hard clinical outcomes (hepatic decompensation, HCC, cardiovascular mortality) remain evidence gaps to be addressed by the ongoing 54-month MAESTRO-NASH and MAESTRO-NASH-OUTCOMES trials 5.
Safety and Tolerability Profile
Common Adverse Events
Gastrointestinal events dominate the safety profile and are generally mild to moderate and early in onset 12.
| Adverse Reaction | Placebo (EAIR/100 PY) | 80 mg (EAIR/100 PY) | 100 mg (EAIR/100 PY) |
|---|---|---|---|
| Diarrhea | 14 | 23 | 33 |
| Nausea | 9 | 18 | 15 |
| Pruritus | 4 | 6 | 10 |
| Vomiting | 4 | 7 | 8 |
| Constipation | 4 | 5 | 8 |
| Abdominal pain | 4 | 5 | 7 |
| Dizziness | 1 | 4 | 4 |
Diarrhea onset was earlier with higher dose (median 6 days at 100 mg vs 39 days for placebo) but median duration was similar (~20 days for both resmetirom doses) 1. Diarrhea and nausea were the most common causes of treatment discontinuation. Serious adverse events were comparable across arms: 10.9% (80 mg), 12.7% (100 mg), and 11.5% (placebo) 6.
Labeled Warnings and Precautions
- Hepatotoxicity: One documented case of drug-induced autoimmune-like hepatitis (DI-ALH) with ALT 58× ULN, AST 66× ULN, and TB 15× ULN; resolved upon discontinuation 1. Monitor liver tests at baseline and periodically; discontinue if hepatotoxicity is suspected.
- Gallbladder events: Cholelithiasis, acute cholecystitis, and obstructive pancreatitis were observed more frequently versus placebo (all EAIRs <1 per 100 PY). Interrupt treatment during acute gallbladder events 1.
- Thyroid function: Mean free T4 (FT4) decreases of 13% (80 mg) and 17% (100 mg) at 12 months; minimal changes in active T3 or TSH; no associated clinical findings 1.
- Liver enzyme elevations: Mean ALT/AST rises <1.5× baseline in first 4 weeks, returning to baseline by week 8 1.
- Hepatic impairment / limitation of use: REZDIFFRA has no labeled contraindications, but use should be avoided in patients with decompensated cirrhosis; moderate or severe hepatic impairment (Child-Pugh B or C) increases resmetirom exposure 1.
- No dosage adjustment required for mild hepatic impairment (Child-Pugh A) or mild-to-moderate renal impairment 1.
Patient Selection and Treatment Positioning
The approved indication is noncirrhotic MASH with moderate-to-advanced fibrosis (F2–F3), to be used alongside diet and exercise 34. An expert panel has emphasized the practical challenge of noninvasively identifying F2–F3 patients while excluding cirrhosis, recommending staged use of FIB-4, ELF scores, VCTE, and MRI-PDFF before resorting to biopsy 79.
Special Populations
- Cirrhosis (Child-Pugh A): Open-label data suggest noninvasive benefit; formal recommendations await MAESTRO-NASH-OUTCOMES results 25.
- Decompensated cirrhosis: Avoid 1.
- Renal impairment: No dose adjustment is recommended for patients with mild, moderate, or severe renal impairment; severe renal impairment increases resmetirom exposure by approximately 1.5-fold in pharmacokinetic studies 1.
- Pregnancy/lactation: No human data; adverse embryo-fetal effects in rabbits at ≥3.5× maximum recommended dose; breastfeeding risks unknown 1.
- Older adults (≥65 years): 25% of MAESTRO-NASH participants; no efficacy difference but numerically higher adverse event incidence 1.
Implementation and Monitoring in Practice
Initiation Checklist
| Step | Action |
|---|---|
| Confirm indication | Noncirrhotic MASH with fibrosis F2–F3 (biopsy or validated noninvasive staging: FIB-4, ELF, VCTE, MRI-PDFF) |
| Baseline labs | ALT, AST, total bilirubin, alkaline phosphatase; FT4, TSH; fasting lipid panel; renal function |
| Baseline imaging | VCTE or MRE (liver stiffness); MRI-PDFF for hepatic fat quantification |
| Review co-medications | Assess statin dose (cap per DDI table above); avoid gemfibrozil; adjust dose if on clopidogrel |
| Weigh patient | <100 kg → 80 mg once daily; ≥100 kg → 100 mg once daily |
| Patient counseling | Swallow tablets whole; report jaundice, RUQ pain, severe GI symptoms; register pregnancy if applicable |
| Early follow-up (4–8 weeks) | Assess GI tolerability; recheck liver enzymes |
| Periodic monitoring | Monitor liver tests and lipid profile during treatment; monitor thyroid function according to baseline thyroid status and clinical context rather than uniformly in all patients. Reassess treatment response with appropriate noninvasive liver disease assessments over time. |
| Discontinuation threshold | Suspected hepatotoxicity; acute gallbladder event; persistent intolerance |
Market Access and Adoption Drivers/Barriers
Rezdiffra received FDA accelerated approval on March 14, 2024, based on surrogate histologic endpoints, with a postmarketing commitment to complete the 54-month MAESTRO-NASH confirmatory trial 3. The EMA CHMP issued a conditional marketing authorisation recommendation on June 20, 2025 (MASH terminology), requiring completion of the pivotal and one supportive trial 4. Regulatory status in China (NMPA) was not documented in the retrieved materials. Payer coverage criteria, biopsy requirements for prior authorization, and cost/budget impact data were not available in the retrieved materials. Public guidance has since expanded beyond the expert panel publication; notably, AASLD issued an October 2024 practice-guidance update addressing resmetirom use in MASLD/MASH.
Post-Marketing Commitments and Evidence Gaps
The ongoing 54-month MAESTRO-NASH trial will provide confirmatory long-term histologic and clinical outcome data 35. MAESTRO-NASH-OUTCOMES (n=700; Child-Pugh A MASH cirrhosis) is evaluating time-to-hepatic-decompensation events but has not yet reported outcomes 5. Critical unanswered questions include: durability of histologic benefit beyond 12–24 months; prevention of cirrhosis progression, hepatocellular carcinoma, and hepatic decompensation; cardiovascular event reduction; and optimal sequencing or combination with GLP-1 receptor agonists. Data readouts from these endpoints are expected within the next 12–36 months and will be pivotal for full regulatory approval conversion and guideline integration.